Form 4: Neurocrine Biosciences Executive Julie Cooke Reports Stock Transactions
SEC Form 4 Filing
Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, reported the vesting of restricted stock units and subsequent sale of shares under pre-arranged trading plans.
Summary
- On January 31, 2025, Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, reported transactions involving the company's common stock.
- Cooke acquired 1,740 shares of common stock upon the vesting of restricted stock units (RSUs) at a price of $0.
- Simultaneously, Cooke disposed of 916 shares at a weighted average price of $152.8879 and 824 shares at a weighted average price of $152.8879.
- These sales were executed under Rule 10b5-1 trading plans adopted on September 1, 2022, and March 14, 2024.
- Following these transactions, Cooke directly owns 18,202 shares and indirectly owns 16,538 shares through the Cooke Family Trust of 2004.
- Cooke also directly owns 1,741 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports routine stock transactions by an executive. There is no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are subject to regulations to prevent insider trading and ensure transparency.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly listed companies like Neurocrine Biosciences.
- Companies like Amgen, Biogen, and Gilead Sciences also have executives who regularly report stock transactions via Form 4 filings.
- The use of 10b5-1 trading plans is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders as they are routine and conducted under pre-arranged trading plans.
- The disclosure provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| September 1, 2022 | Date of adoption of a Rule 10b5-1 trading plan by the Reporting Person. |
| March 14, 2024 | Date of adoption of a Rule 10b5-1 trading plan by the Reporting Person. |
| December 28, 2004 | Date of establishment of the Cooke Family Trust. |
| January 31, 2022 | Date the Restricted Stock Unit was granted to the Reporting Person. |
| January 31, 2023 | Date 1,740 shares vested from the Restricted Stock Unit. |
| January 31, 2024 | Date 1,740 shares vested from the Restricted Stock Unit. |
| January 31, 2025 | Date of the reported transactions (vesting of RSUs and sale of shares). |
| January 31, 2025 | Date 1,740 shares vested from the Restricted Stock Unit. |
| January 31, 2026 | Date 1,741 shares will vest from the Restricted Stock Unit. |
| February 04, 2025 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.